SCOTTSDALE, Ariz., Aug. 5 AZ-MedPredict-COPD
SCOTTSDALE, Ariz., Aug. 5 /PRNewswire/ -- MedPredict, a global provider of
pharmaceutical competitive intelligence and market research, has published a
new report providing critical strategic insight for pharma and biotech
companies with a stake in the market for asthma and chronic obstructive
pulmonary disease (COPD) therapies.
In this report, entitled "MedPredict Thought Leader Insight & Analysis:
Respiratory Disorders," a panel of world-class pulmonologists outlines the
unmet needs in the treatment of asthma and COPD and then drills down into
subtle differences between combination therapies, translating their attributes
into the benefits each delivers. These discussions encompass once- and twice
daily LABAs (long-acting beta agonists), steroids, leukotriene inhibitors,
anticholinergics, FLAP, CXCR2 and other mechanisms. The panel also considers
each of these approaches in the context of prn vs. maintenance dosing.
"There is a lot of commercial development activity aimed at identifying
biologicals that have disease-modifying activity, both in asthma and COPD,"
said Jeff Berk, the report's author. "Our panel sorts through the biologicals
in the pipeline, including monoclonals targeting IL-5, IL-9 and IL-13/IL-4,
and picks their favorites." Also addressed in this report:
-- What are the key unmet needs in asthma and in COPD, and which
compounds/combinations are best poised to fill the need gaps?
-- Which of the new biologicals in development show the most promise, and
why? Will these be likely to replace current standard of care?
-- Will developers be able to show disease-modification benefits in COPD?
-- How will the increased mortality seen in the SMART trial affect usage
of LABAs in asthma?
Companies/Partnerships discussed include: Aerovance (Bayer-Schering),
Altair Therapeutics/Isis, Amgen/Takeda Bio, Boehringer Ingelheim, Ception,
Chiesi, Cornerstone BioPharma/Critical Therapeutics/Dey, Forest,
GlaxoSmithKline, GSK/Theravance, GSK/Amira, Merck, Merck/Schering- Plough,
Novartis, Novartis/Genentech, Novartis/Schering-Plough/SkyePharma,
Nycomed/Sepracor, Schering-Plough/ALK-Abello, Sepracor, SkyePharma/Kos/Abbott,
Stallergenes/Paladin, Wyeth.
This report can be purchased by contacting MedPredict.
About MedPredict
MedPredict (http://www.medpredict.com) maintains a proprietary database of
over 1,000 global physician thought leaders, including 40+ specialties in 30+
therapeutic categories. Based on primary interviews with these thought
leaders, MedPredict publishes periodic reports in each category to keep
clients up-to-date on emerging trends and competitive activity. The reports
include thought leader reactions to recent publications and medical
conferences, as well as clinical, regulatory and marketing activity.
SOURCE MedPredict
